Our research projects

Finding drugs which target genes that drive high-risk acute lymphoblastic leukaemia.

Developing more effective treatments for patients who have a low chance of survival, while reducing treatment and side effects for other patients.

Our proposal will deliver novel, less toxic targeted therapies with the potential to advance current treatment regimens for B-ALL. This will improve current outcomes, reduce side-effects in B-ALL patients and ultimately lead to a better quality of life for patients and their families.

Investigating a new method to improve the success of bone marrow transplants, using a different type of blood cells.

Glo-BNHL trial is an international trial that will recruit children across the globe with relapse BNHL and assign them to the trial to receive a novel therapy. We are requesting funds to conduct biological studies alongside the trial to improve our understanding of this cancer.

Immunotherapy could be a potential treatment for ependymoma. To make immunotherapy effective we need to know more about how ependymoma works.

Ewing sarcoma is the second most common bone tumour in young people. The primary goal of this project is to fast-track a targeted drug combination for evaluation in clinical trials, with the aim of improving outcomes and minimising treatment associated morbidities for Ewing sarcoma patients.

Osteosarcoma bone cancer affects teenagers, around half of whom die within 5-years of diagnosis. We think we can solve these problems by modifying immune cells called “gamma-delta T-cells”.

Half of patients Ependymoma (EPN) with no disease after treatment on MRI relapse within 2 years. This suggests that they have low level or minimal residual disease (MRD). Developing an accurate MRD detection test could help improve survival.